Previous 10 | Next 10 |
Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...
Inari Medical Set to Join S&P MidCap 400; Tri Pointe Homes to Join S&P SmallCap 600 Inari Medical Set to Join S&P MidCap 400; Tri Pointe Homes to Join S&P SmallCap 600 PR Newswire NEW YORK , April 28, 2022 /PRNewswire/ -- Inari Medical...
IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the Ba...
IRVINE, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarte...
MedTech stocks are trading sharply higher on Tuesday after the industry bellwether Johnson & Johnson (JNJ) reported better than expected 1Q 2022 sales for its MedTech segment. The iShares U.S. Medical Devices ETF (NYSEARCA:IHI) has recorded the best intraday gain since June 2020, dri...
IRVINE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it has completed the sale of an ...
Inari Medical (NASDAQ:NARI) has priced public offering of 2M shares of its common stock at $81/share. Underwriters over-allotment is an additional 300K shares of common stock. The offering is expected to close on March 15. A quick look at the company's ownership structure: For further detai...
IRVINE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the pricing of an underwritten ...
Gainers: Kala Pharmaceuticals (NASDAQ:KALA) +20%. Natera (NASDAQ:NTRA) +17%. Chemomab Therapeutics (NASDAQ:CMMB) +13%. Selecta Biosciences (NASDAQ:SELB) +11%. Longeveron (NASDAQ:LGVN) +7%. Losers: Sunshine Biopharma (NASDAQ:SBFM) -32%. My...
Inari Medical (NASDAQ:NARI) trades 2.9% down premarket after it commenced an underwritten public offering of 2M shares; underwriters granted 30-day option to purchase up to an additional 300K shares. Offer size, terms not yet decided. For further details see: Inari M...
News, Short Squeeze, Breakout and More Instantly...
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024...
Hagens Berman Encourages NARI Investors with Substantial Losses to Contact Firm Before July 12, 2024 Deadline San Francisco, California--(Newsfile Corp. - June 26, 2024) - Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses no...
2024-06-01 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...